20:43 , Feb 16, 2018 |  BC Week In Review  |  Company News

BMS, Nektar partner on NKTR-214 combos in $3.6B deal

Nektar Therapeutics (NASDAQ:NKTR) partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to develop and commercialize Nektar's NKTR-214 in combination with BMS's anti-PD-1 mAb Opdivo nivolumab and Opdivo plus the pharma’s Yervoy ipilimumab in select solid tumors. The...
23:55 , Dec 18, 2017 |  BC Extra  |  Company News

Regeneron, ISA partner for HPV16-induced cancer combinations

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and ISA Pharmaceuticals B.V. (Leiden, the Netherlands) partnered to jointly conduct clinical trials evaluating ISA's ISA101 in combination with Regeneron's anti-PD-1 mAb cemiplimab (REGN2810, SAR439684) to treat cancer. ISA101 is an...
01:10 , Sep 16, 2017 |  BioCentury  |  Finance

Local leverage

What began as a fund designed to provide Eli Lilly and Co. access to innovation in China has evolved into an independent VC with a focus on innovative Chinese healthcare companies and U.S. biotechs looking...
18:14 , May 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting tyrosine phosphorylation of Shc could help treat breast cancer. In a mouse model of breast cancer, knock-in of a phosphotyrosine-deficient Shc variant delayed time to...
16:19 , Apr 25, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling T cell clonality or DNA copy number loss burden could help predict therapeutic response to sequential anti- CTLA-4 and anti- PD1 therapies. In melanoma patients treated with an anti-CTLA-4 mAb followed by...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD40; programmed cell death 1 (PD-1; PDCD1; CD279); programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)

Cancer INDICATION: Breast cancer; renal cancer Mouse studies identified an agonist antibody against CD40 that could help treat PD-1 inhibitor-resistant breast and renal cancers. Screening of immune cell-targeting antibodies in a mouse model of PD-1...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: T cell immunoglobulin and mucin domain 3 (TIM3; HAVCR2); programmed cell death 1 (PD-1; PDCD1; CD279); programmed cell death 1 ligand 1 (PD-L1; B7

Cancer INDICATION: Non-small cell lung cancer (NSCLC) Patient sample and mouse studies suggest inhibiting TIM3 could help treat checkpoint inhibitor-resistant NSCLC. In pleural effusion samples from NSCLC patients, T cells from two patients with treatment-induced...
07:00 , Jun 8, 2015 |  BioCentury  |  Product Development

Out with the old

Data presented at the American Society of Clinical Oncology meeting in Chicago in previously treated multiple myeloma offer the tantalizing prospect that new regimens could move up to supplant Velcade bortezomib as standard of care...
08:00 , Jan 29, 2015 |  BC Innovations  |  Strategy

PD-1 matchmaking

The rush to find combinations of PD-1 inhibitors and established cancer therapies marks the end of the beginning, rather than the beginning of the end, of the search for ways to extend use of checkpoint...
08:00 , Jan 29, 2015 |  BC Innovations  |  Product R&D

Company checkpoints

The spate of biotechs announcing new targets, combinations or milestones in the PD-1 space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of...